Keyphrases
GBA1
100%
Parkinson's Disease
100%
Glucocerebrosidase
100%
Clinical Trials
33%
Trial Success
33%
Monoallelic
22%
Parkinson's Progression Markers Initiative
22%
Alpha-synuclein (α-syn)
22%
Clinical Features
22%
Peripheral Markers
11%
Clinical Data
11%
Disease-modifying Therapy
11%
Longitudinal Samples
11%
Parkinson's Disease Diagnosis
11%
Levels of Association
11%
Key Biomarkers
11%
Biomarker Testing
11%
Disease Potential
11%
Pathophysiologic Mechanisms
11%
Combined Samples
11%
Pathophysiology
11%
Genetic Modifiers
11%
Non-motor
11%
Clinical Outcomes
11%
Etiology of Parkinson's Disease
11%
Biomarker Studies
11%
Pharmacodynamic Markers
11%
Genetic Factors
11%
Gene mutation
11%
Longitudinal Change
11%
Clinical Decline
11%
Cognitive Burden
11%
Activity Level
11%
Harvard
11%
Peripheral Biomarkers
11%
Lipid Levels
11%
CSF Markers
11%
Lipids
11%
Longitudinal Assessment
11%
Idiopathic Parkinson's Disease
11%
Proposed Work
11%
GBA1 Gene
11%
Potential Therapeutics
11%
Biochemical Measures
11%
Enzymatic Activity
11%
Biospecimens
11%
Trial Development
11%
Rapid Progression
11%
GBA mutations
11%
Etiologic Mechanisms
11%
Epigenomics
11%
Biochemistry, Genetics and Molecular Biology
Glucocerebrosidase
100%
Glucosylceramidase
100%
Clinical Trial
60%
Enzyme
40%
Biomarker Study
20%
Genetics
20%
Genetic Determinism
20%
Lipid
20%
Pharmacodynamics
20%
Lipid Level
20%
Gene Mutation
20%
Enzyme Activity
20%
Alpha-Synuclein
20%
Synuclein
20%
Pharmacology, Toxicology and Pharmaceutical Science
Glucosylceramidase
100%
Biological Marker
100%
Parkinson's Disease
100%
Clinical Trial
25%
Clinical Feature
16%
Biomarker Study
8%
Alpha Synuclein
8%
Pharmacodynamics
8%
Pathophysiology
8%
Synuclein
8%
Disease
8%